NCT03087201 - CANNAbinoids in the Treatment of TICS (CANNA-TICS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions

Tourette SyndromeTic Disorders

Interventions

DRUG

nabiximols

"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"

DRUG

placebo

analogous to experimental intervention

Trial Locations (6)

Unknown

Uniklinik RWTH Aachen, Psychiatry and Psychotherapy, Aachen

University Hospital Cologne, Psychiatry and Psychotherapy, Cologne

University of Freiburg, Psychiatry and Psychotherapy, Freiburg im Breisgau

Hannover Medical School, Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hanover

University Hospital Schleswig-Holstein, Institute of Neurogenetics, Department of Pediatric and Adult Movement Disorders and Neuropsychiatrics, Lübeck

LMU Munich, Psychiatry and Psychotherapy, Munich